Report Subject - Medical Affairs - Page 1

Learn More Health Insurance Disruptors: Going Digital

Health insurance: how to thrive in an increasingly digital health world Health insurers are being challenged to develop a portfolio of digital services with limited knowledge of their effectiveness and at a considerable...

Compare
Learn More Regulating Digital Health

As digital health progressively enters mainstream therapy, how should it be regulated and to what outcome? Digital health is booming and as investment in digital health technology grows more products and services will...

Compare
Learn More The Future of Disease Interception

What does pharma need to do to develop this radical health model of the future? Disease interception is a novel healthcare model that identifies, treats and sometimes cures disease before it is fully manifested. There...

Compare
Learn More The Future of Virtual Healthcare

What strategy should pharma be pursuing in virtual healthcare? Applications for virtual healthcare engagement are quickly evolving beyond websites and apps towards advanced tools such as virtual assistants and virtual...

Compare
Learn More Financing High-Cost Therapies through Reinsurance

Could reinsurance allay health insurers' fear about high cell and gene therapy costs? With the prospect of many cell and gene therapies coming to market in the medium term, often with record breaking list prices and...

Compare
Learn More The Impact of Drug Compounding on Pharma

Drug compounding meets unmet clinical needs, widens therapy choice and expands patient access to medicines. What are the lessons and opportunities for pharma? Drug compounding is a fast growing sector meeting the needs...

Compare
Learn More The Future of CRISPR

Where will CRISPR deliver real value? Investors and pharma are enthusiastic about CRISPR gene editing technology: not only can it be used to develop new therapeutics, it has become a powerful tool in drug discovery,...

Compare
Learn More Virtual Clinical Trials: The future of drug development?

How viable are virtual clinical trials as a model for conducting clinical research? With our deepening understanding of disease and ever more targeted therapies, slow and costly traditional clinical trials alone are no...

Compare
Learn More Medical-grade Wearable Technology: Applications and implications for pharma

Leveraging clinical wearables and digiceuticals to gain competitive advantage From smart wristbands and glasses to tiny sensors in pills, the latest advances in medical-grade technology are unlocking new opportunities...

Compare
Learn More Artificial Intelligence and Machine Learning: Applications in Pharma

Where can Artificial Intelligence and Machine Learning really drive change in pharma's business? Artificial Intelligence (AI) and Machine Learning (ML) have the potential to unlock new insights and massively improve...

Compare
Learn More Voice Assistants and Medical Chatbots in Healthcare

Voice activated technology: What are the potential benefits for pharma? The use of voice-controlled assistants (VCAs) such as Apple's Siri and Amazon's Alexa are familiar to many of us in our daily lives. But how might...

Compare
Learn More Gene Therapy: Commercial Opportunities and Challenges for Pharma

As gene therapies for major diseases accelerate from the development pipeline, how can pharma exploit near-term opportunities and protect its business going forward? As gene therapies for major diseases accelerate from...

Compare
Learn More Digital Therapeutics: Taking digital health to a new level

The Digital Therapeutics field is exploding: what does pharma need to know - and do - to get on board? Evidence-based and reimbursed digital therapeutics (DTx) are now part of the health delivery landscape. They hold...

Compare
Learn More Blockchain: Transformational change for Pharma?

Is blockchain really the technology that can revolutionise pharma's business? Rapidly developing Blockchain technology can deliver transparent, secure and reliable data sharing. It also has the prospect of streamlining...

Compare
Learn More The Impact of Nanomedicine in the Pharma Industry

Can nanomedicines really offer pharma a compelling alternative approach to precision medicines? Delivering accurate diagnosis for clinicians, safer medicines for patients and lower costs through reduced waste and costly...

Compare
Learn More Medical Affairs in Emerging Markets

How can medical affairs capability be enhanced to unlock the Brazilian, Russian, Indian and Chinese pharma markets? The pharma markets of Brazil, Russia, India and China (BRIC) are becoming increasingly complex with...

Compare
Learn More MSL stakeholder engagement: meeting expectations

MSL Stakeholder Engagement–Meeting Expectations In this report, FirstWord identifies practical solutions to the stakeholder engagement challenges faced by medical science liaisons (MSLs) teams in 2017. Discover...

Compare
Learn More Charting MSL Activity and Performance (2017)

A unique survey-based report providing key insights and actionable intelligence about MSL activity and performance. Charting MSL Activity and Performance (2017) distils key findings from one of the most comprehensive...

Compare
Learn More Medical Affairs in Orphan Drugs

Orphan drugs: Is your medical affairs team leading the fray or lagging behind? Traditional commercial models simply don’t work for orphan drugs, not least because the physician and patient populations are so...

Compare
Learn More The Future of Medical Affairs

What are the future opportunities and challenges for medical affairs? As the interface between companies and KOLs, HCPs, payers and patients, medical affairs has grown rapidly in importance. And demands are set to...

Compare

Browse by

FirstWord Medical Affairs Reports